Abstract
Objective: to study biomolecules associated with pathology in the respiratory system, in particular, with the development of chronic bronchitis in patients with abdominal obesity. Materials and methods: This is a pilot study. The main group consisted of 158 people with chronic bronchitis, divided into two subgroups: one with abdominal obesity, and the other without it. The control group consisted of 68 people without chronic bronchitis. We determined the blood levels of SP-A, SP-D, α1-antitrypsin, CC16, PARC, and RELM-β. Results: In the first subgroup, patients significantly more often complained of coughing, experienced shortness of breath 1.5 times more often with light physical exertion and 2.7 times more often with moderate physical exertion. In these patients, a Tiffeneau–Pinelli index (FEV1/FVC) below 70% was 1.8 times more common, more patients had FEV1 and FVC of less than 80%, and presented a statistically significant decrease in SP-A, α1-antitrypsin, CC16 levels and an increase in PARC levels than in the second subgroup. Conclusion: In patients with chronic bronchitis and abdominal obesity, there is a decrease in the levels of SP-A, α1-antitrypsin, CC16 and an increase in the level of PARC compared with patients without abdominal obesity, which is probably due to the presence of an additional source of chronic inflammation associated with adipose tissue.
Highlights
There have been more and more studies describing the clinical and functional features of the combined course of Chronic bronchitis (CB) and abdominal obesity (AO), which is a predictor of an unfavorable prognosis of the disease for smokers and for people who have never smoked [8,9,10]
The results showed that the relative chance of developing chronic bronchitis was only associated with an increase of Resistin-like molecule-β (RELM-β) level in the blood (OR = 1.01, 95% CI 1.003–1.017, p = 0.004)
Our study showed a significant decrease in the level of α1-antitrypsin in patients with chronic bronchitis and abdominal obesity
Summary
Chronic bronchitis (CB) is a clinical phenotype in COPD and is defined as the presence of cough and sputum production for at least three months in each of two consecutive years. The pathomorphological basis of CB is epithelial metaplasia, accompanied by excessive mucus production in response to respiratory tract chronic inflammation. Studies show that in COPD, inflammation of the respiratory tract is not limited to the lungs and can go beyond it, taking the character of systemic inflammation [1,2,3,4,5,6,7]. There have been more and more studies describing the clinical and functional features of the combined course of CB and abdominal obesity (AO), which is a predictor of an unfavorable prognosis of the disease for smokers and for people who have never smoked [8,9,10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
